The discussion Monday night wasn’t necessarily about the creation of the DDA, but about the $200,000 that the city planned to ...

The Company still expects to issue its third quarter 2025 earnings release and financial supplement today after market. The Company is providing the following preliminary performance metrics: About ...

Even in times like these, you can still find quiet bipartisan bonds at the Capitol if you know where to look, Bradford Fitch writes.

President Trump’s post raises technical questions about how and if the United States could “immediately” return to nuclear ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...

Reaffirms 2025 adjusted earnings guidance in the range of $4.00 to $4.20 per share, excluding merger-related costs, same as prior GAAP ...

Unprogrammed appropriations were a magnet for corruption, a source of billions in kickbacks for legislators and other ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

"Our portfolio of high-quality assets continued to deliver strong results, generating record revenue, earnings, and cash flow for the first nine months of 2025," said Randy Smallwood, Chief Executive ...

Bank of the Philippine Islands ( OTCPK:BPHLY) Q3 2025 Earnings Call October 30, 2025 4:00 AM EDT ...

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - ...